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The  global  health  community  is  beginning  to gain  an  understanding  of the  global  burden of  norovirus-
associated  disease,  which  appears  to have  signiﬁcant  burden  in  both  developed-  and  developing-country
populations.  Of particular  importance  is  the  growing  recognition  of  norovirus  as  a  leading  cause  of  gas-
troenteritis  and  diarrhea  in countries  where  rotavirus  vaccine  has  been  introduced.  While  not  as  severe
as  rotavirus  disease,  the sheer  number  of  norovirus  infections  not  limited  to  early  childhood  makes
norovirus  a formidable  global  health  problem.  This article  provides  a landscape  review  of  norovirus  vac-
cine development  efforts.  Multiple  vaccine  strategies,  mostly  relying  on virus-like  particle  antigens,  are
under development  and  have  demonstrated  proof  of  efﬁcacy  in human  challenge  studies.  Several  are
entering  phase  2 clinical  development.  Norovirus  vaccine  development  challenges  include,  but  are  not
limited  to:  valency,  induction  of  adequate  immune  responses  in  pediatric  and  elderly  populations,  and
potential  for  vaccine-strain  mismatch.  Given  current  strategies  and  global  health  interest,  the  outlook  for
a  norovirus  vaccine  is  promising.  Because  a norovirus  vaccine  is expected  to  have  a  dual  market  in  both
developed  and  developing  countries,  there  would  likely  be  scale-up  advantages  for  commercial  devel-
opment  and  global  distribution.  Combination  with  or expression  by  another  enteric  pathogen,  such as
rotavirus,  could  also  enhance  uptake  of a norovirus  vaccine.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC. About the disease and pathogen
Noroviruses (NoVs) cause acute, debilitating gastroenteritis
haracterized by vomiting and diarrhea. The US Centers for Dis-
ase Control and Prevention (CDC) estimate that it is the most
ommon cause of acute gastroenteritis in the United States with
1 million cases each year and an estimated 70,000 hospitaliza-
ions and 8000 deaths nationwide [1]. NoVs have also emerged as
n important cause of gastroenteritis worldwide. These infections
an occur in all age groups and commonly result in signiﬁcant mor-
idity and mortality, particularly in the very old and very young. A
ecent systematic review [2] estimated NoV prevalence to be at 14%
nd found that rates of NoV are higher in community-based and
utpatient health care settings compared to hospital-associated
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cases. While this may  seem to suggest that NoV causes less severe
cases than other causes of diarrheal disease, the sheer frequency
of illness results in a larger burden of severe NoV disease overall
[2]. It is estimated that up to 200,000 children die from compli-
cations of NoV infection worldwide annually [3]. In addition, NoV
illnesses and outbreaks exact a signiﬁcant socioeconomic toll on
businesses, hospitals, schools, and other closed settings such as dor-
mitories, military barracks, and cruise ships. However, there are
current gaps in the epidemiology of NoV, particularly for lesser-
developed countries where advanced molecular diagnostics have
been limited. Global regions such as Africa and Southeast Asia are
not well represented by data, and case deﬁnitions have not broadly
included the full spectrum of case presentations, including vomi-
ting as the predominant symptom. Thus, global NoV incidence
is likely underestimated and additional high-quality studies are
needed.
The Norovirus genus is divided into ﬁve genogroups (I–V), with
GI, GII and GIV causing human infections. Each genogroup is fur-
ther subdivided into genotypes based on analysis of the amino
acid sequence of its major viral capsid protein VP1. Norwalk virus,
the prototype human NoV species, is classiﬁed as a GI virus. Over
80% of conﬁrmed human NoV infections are associated with geno-
type GII.4. Serotyping—as commonly done for viruses through
neutralization assays—is impossible for NoV, as the virus cannot
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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e cultured in vitro. Therefore, the true biological signiﬁcance of
hese classiﬁcations is unknown. Pathogenesis is thought to be
ependent on binding of the virus to human histoblood group
ntigens (HBGAs) on the epithelium of the small intestine. HBGAs
re glycans found on the surface gut epithelium (as well as red
lood cells, saliva, and respiratory epithelia). The expression of
hese glycans has been shown to affect the susceptibility to infec-
ion with certain NoV, namely in human challenge studies where
nly individuals who have a functional glycosylase enzyme and
onsequently express certain HBGAs are susceptible to infection
ith Norwalk virus [3]. Studies have also described resistance
o infection from other NoV genotypes due to a non-functional
lycosylase.
The inability to culture NoV hampers research on pathogenesis,
accine development, and diagnostics. Although molecular diag-
ostics are available, the fact that NoV can be shed at low levels for
ong periods of time after infection (average 4 weeks) makes disease
ttribution difﬁcult. Recent attempts have been made to rigorously
eﬁne the burden of acute enteric diseases in the developing world.
he Global Enteric Multicenter Study (GEMS) used a conventional
non-quantitative) multiplex real-time polymerase chain reaction
RT-PCR) study for the detection of several enteric RNA viruses,
ncluding NoV [4]. GEMS attributed moderate-to-severe diarrheal
isease to NoV in only one of its seven sites across Africa and
sia. However, the case-control study design utilized in the GEMS
tudy in which control selection may  not have eliminated healthy
ndividuals who had prior norovirus in the preceding month (i.e. eli-
ibility excluded only those with diarrhea reported in past 7 days)
ay  have not been able to differentiate between NoV positivity
n acute disease and asymptomatic controls and, thus, is likely to
ave poor sensitivity and speciﬁcity and underestimate the role
f NoV as a cause of diarrhea, especially in the high-transmission
ettings [5]. In fact, recent results from the multicenter MAL-ED
irth cohort study, which controlled for a longer duration of shed-
ing in controls, found that NoV GII was responsible for the most
ases of diarrheal illness among children overall and particularly
n countries where rotavirus vaccine had been introduced [6].
lthough the MAL-ED observation is consistent with the ﬁnding
hat NoV rates are higher in community-based studies compared
o hospital-based studies, indicating that the disease has a milder
resentation. However, the fact that NoV is the leading cause of clin-
cal diarrhea in the United States also suggests that NoV could likely
e a cause of severe disease among children in lesser-developed
ountries, a notion furthered by the WHO  Food Epidemiology
eference Group (FERG) which has identiﬁed norovirus as one
f the most important pathogens transmitted by food in the
orld.
In order to more accurately attribute pathogen etiology at the
npatient, outpatient, and community levels, future epidemiolog-
cal studies should consider including quantitative diagnostics,
requent sampling, and well-considered control subjects in their
esign. Furthermore, to attain high-quality global data to inﬂuence
olicy decisions and generate global commitment, a surveillance
etwork similar to that which was established in advance of
otavirus vaccine introduction may  be needed.
NoV is also highly transmissible, requiring a very low infec-
ious dose of <10 to 100 virions, causing acute illness of fever,
ausea, vomiting, cramping, malaise, and diarrhea persisting for
wo to ﬁve days. The disease is mostly self-limiting, although
evere outcomes and longer durations of illness are more likely to
e reported among the elderly and immunocompromised groups.
ecause immunity after infection is limited in duration and appears
train-speciﬁc, all age groups are susceptible. Apart from sup-
ortive care such as oral rehydration, there are no treatments
urrently available to decrease the severity of NoV-induced illness.
n countries where sustained universal rotavirus vaccination hase 34 (2016) 2895–2899
been introduced, NoVs have become the main cause of gastroen-
teritis in children.
2. Overview of current efforts
2.1. Biological feasibility for vaccine development
There are currently no licensed vaccines for NoV. While cur-
rent estimates of under-ﬁve mortality rank NoV (71,000) less than
rotavirus (197,000) and enteropathogenic E. coli (79,000), NoV is
above enterotoxigenic E. coli (42,000) [7]. Additionally, the high
estimated morbidity attributed to NoV, which occurs in all age
groups in both developed and developing countries, suggests that
the global health value of a NoV vaccine may  rank equivalently
with other enteric vaccines under development when evaluating
both disability and mortality measures.
A recent review on NoV vaccine development explored the fac-
tors complicating vaccine design [8]. These include the lack of
appropriate model systems to explore pathogenesis and vaccine
target efﬁcacy, unknown duration of protective immunity, anti-
genic variation among and within genogroups and genotypes, and
unknown effects of pre-exposure history. Preclinical development
is challenging due to the lack of relevant models—currently limited
to a chimpanzee model, which has been halted due to ethical
restrictions on the use of nonhuman primates, and a gnotobiotic
pig model—and the lack of NoV cell culture.
The inability to culture NoV has obviously limited any traditional
whole-cell vaccine approaches, but recombinant technology—more
precisely, NoV-recombinant virus-like particles (VLPs) produced
by the expression and spontaneous self-assembly of the major
capsid protein VP1—has played a major role in generating the
current body of knowledge and leading approaches in NoV vac-
cine development. Efﬁcacy trials will be essential in answering
the issues raised above, including duration of vaccine-induced
immunity, implications of antigenic diversity and drift on vaccine-
induced protection, and the consequence of pre-existing immune
responses.
Despite the limitations, vaccine feasibility has been convincingly
demonstrated with the development of a vaccine candidate based
on a recombinant approach using a self-assembling virus-like par-
ticle (VLP) that has shown protection against disease in two  human
challenge efﬁcacy studies. Currently, it is being developed as a biva-
lent GI.1/GII.4 vaccine administered intramuscularly. NoVs have
extensive antigenic and genetic diversity, with more than 25 geno-
types recognized among the three genogroups containing human
viruses. This has best been documented with the GII.4 genotype
(dominant strain replacement every two  to four years), though GI.1
and GII.2 isolates have also demonstrated stability over the past 30
years. While signiﬁcant variation is known to occur with the epi-
topes responsible for seroresponse, there is evidence to suggest
that more conserved domain epitopes across groups and strains
may  serve as a protective antigen in an adjuvanted vaccination
regimen. There are also preclinical and clinical data that support
broadened activity beyond the vaccine VLP strains. More encour-
agingly, although there is a lack of correlation of pre-existing serum
antibody (as measured by ELISA) with protection from infection, the
presence of serum antibodies that block binding of NoV virus-like
particles (VLPs) to HBGAs have been associated with a decreased
risk of infection and illness following homologous viral challenge.
This blocking assay could play a critical role in facilitating further
development and optimization of this vaccine. If a vaccine based
on this bivalent approach is developed and licensed, future stud-
ies will need to determine whether the broadly protective immune
responses elicited by the vaccine remain effective as strain varia-
tion occurs naturally (or in response to wide-spread vaccination).
Modiﬁcation of the formulation may  be required if non-vaccine
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trains emerge for which the vaccine does not induce functional
ntibodies.
Based on modeling of epidemiological data, protective immu-
ity after natural NoV infection may  persist between four and eight
ears. Early human challenge/rechallenge studies have observed
rotection from six months to two years. Thus, duration of protec-
ion is still unknown and the rapid incubation period from infection
o illness onset may  challenge the timing of effective memory
esponse activation. The inﬂuence of multiple exposures and pre-
xisting immunity may  also complicate the vaccine approach and
mmune responses.
.2. General approaches to vaccine development for low- and
iddle-income country markets
From a low- and middle-income-country perspective, there are
nique issues to consider for vaccine development and feasibility.
ose number and schedule are important, and circulating strains
ay  be different compared to those found in developed countries.
urthermore, the current vaccine approach for an indication in
dults is based on an intramuscular injection of the vaccine with
n effective immune response that is thought to rely in part on
he boosting of memory from previous natural infection. As this
accine would likely be targeted to younger children, the effective-
ess of such a vaccine in a naïve infant could be less. It will be
ost interesting to learn about the priming of functional antibody
esponses from current phase 2 trials in these settings which are
urrently underway (ClinicalTrials.gov Identiﬁer: NCT02153112).
f necessitated, an alternative mucosal priming-parenteral boost
nd/or adjuvant may  be necessary, but this would complicate
he development of a vaccine for use in a resource-limited
etting.
From a developed-country perspective, there are a number of
arget populations and indications for which a norovirus vaccine
ould be developed and bring substantial public health value. These
nclude not only travelers to lesser-developed countries and mil-
tary personnel on deployment, but also healthcare workers and
ood handlers in developed countries who are at higher risk given
he frequency and impact of NoV outbreaks in these populations.
lderly populations in group and institutional settings also expe-
ience frequent outbreaks and tend to have more severe disease
nd associated mortality, but may  present a challenge to induce
ffective immune responses.
While more high-quality data on the epidemiology of NoV across
ges and geographic areas are needed, it is clear that NoV has a
lobal distribution that causes signiﬁcant morbidity and mortality.
 recent systematic review on mortality due to diarrhea among
hildren less than ﬁve years of age found that NoV was associ-
ted with hospitalization in approximately 14% of cases, behind
otavirus (38%) and enteropathogenic E. coli (15%) [7]. There is a
earth of data from Africa, where the effects of NoV-associated
astroenteritis may  be more severe. Furthermore, because NoV
ffects all ages, it likely contributes to additional global disease bur-
en beyond mortality. Forthcoming results from the World Health
rganization (WHO) Foodborne Epidemiology Reference Group
hould provide better estimates for relative disease burden across
ge strata to consider.
In summary, based on available epidemiological data, it appears
hat NoV has a similar epidemiology to rotavirus in incidence
mong children less than ﬁve years of age, with multiple infections
nd the highest incidence rates occurring in the ﬁrst two years of
ife. Changing dynamics in strain variation and circulation could
ikely also extend the high incidence beyond two years of life. A
uccessful vaccination strategy would therefore need to target chil-
ren at the earliest opportunity in order to have maximum public
ealth beneﬁt.e 34 (2016) 2895–2899 2897
3. Technical and regulatory assessment
Favorable advances have been made with a bivalent VLP-based
vaccine. Firstly, proof of concept for efﬁcacy has been recently
demonstrated in a human challenge model with 50 vaccine and
48 placebo recipients, which observed 52% protection against
all severity levels of disease (p = 0.028) and 68% (p = 0.068) and
100% (p = 0.054) protection against moderate-to-severe disease and
severe disease only, respectively [9]. Furthermore, evidence for a
correlate of protection is emerging based on induction of anti-
bodies which bind to HBGAs [10]. HBGAs are hypothesized to
serve as attachment factors for noroviruses, and data from clinical
trials show that vaccinated subjects with higher HBGA-blocking
antibodies had lower levels of infection and less severe disease.
Furthermore, HBGA-blocking antibodies found among placebo
recipients at pre-challenge were associated with protection.
An important concern about NoV is that strains change over
time, and immune response to natural infection does not provide
effective neutralizing antibodies for heterologous strains. However,
a recent report describes broadly reacting HBGA-blocking anti-
bodies in the recipients of a candidate bivalent VLP (GI.1/GII.4)
vaccine for diverse strains and genotypes not included in the
vaccine, suggesting broadly protective capability of the vaccine
[11]. While these studies are encouraging, translation to low-
and middle-income countries will present challenges, including
adequate immune responses to a variety of circulating strains,
substantiation of a correlate of protection that is also present in
developed-country settings, and integration of a NoV vaccine into
a crowded EPI immunization schedule. Limited data from cohort
studies suggest that the timing of a vaccine may be important. In
one birth cohort study in Peru it appears that norovirus has a sim-
ilar epidemiology to rotavirus in incidence under 5 years of age
occurring within the ﬁrst year of life though highest incidence and
multiple infections occur in the ﬁrst two years of life [12]. How-
ever, changing dynamics in strain variation and circulation could
likely extend the high incidence beyond 2 years of life. Additionally,
more research is needed on virus-host associations and epidemi-
ology to ensure adequate strain coverage of the current bivalent
vaccine approach. Speciﬁcally, there is a need for rigorous studies
that can accurately describe NoV prevalence and disease status in
developed and developing world settings through the use of more
sensitive and speciﬁc indicators of genotype-speciﬁc NoV exposure
from serum.
For an adult traveler vaccine indication, further Phase 2 clinical
development is being planned for the bivalent VLP parenteral vac-
cine being developed by Takeda Vaccines. These types of studies
can be challenging due to the lack of predictability of disease out-
breaks, the common ﬁnding of copathogenicity of diarrheal disease,
frequent mismatch of vaccine strains with virus strains encoun-
tered, as well as ﬁeld study challenges in following and collecting
specimens from travelers. Despite these challenges, travelers’ diar-
rhea vaccine studies have successfully been performed in the past.
Trials among elderly in nursing homes could also be considered,
although lack of predictability of outbreaks and adequate immune
responses may  present similar challenges. Favorable results from
trials in adult travelers or other high-risk populations in devel-
oped countries would support the effectiveness of such a vaccine
approach in low- and middle-income country populations.
For a developing-country vaccine indication, plans for a multi-
site, pediatric, age-descending Phase 2 study in Colombia, Panama,
and Finland are currently underway (ClinicalTrials.gov Identiﬁer:
NCT02153112). After these introductory clinical trials, rotavirus
vaccine development pathways have demonstrated that there are
sufﬁcient ﬁeld sites, experience, and regulatory pathways to take a
NoV vaccine through large-scale safety studies and pivotal trials in
low- and middle-income countries. Although acute gastroenteritis
2898 M.S. Riddle, R.I. Walker / Vaccine 34 (2016) 2895–2899
Table 1
Development status of current vaccine candidates (POC = proof-of-concept trial).
Candidate name/identiﬁer Developer Pre-clinical Phase I Phase II POC Phase III Refs
G1-I/GII-4 VLP Takeda Vaccines X [13]
[G1-I/GII-4 VLP Arizona State University X None
NoV-VLP/rotavirus VP6 protein combination University of Tampere; MN Pharma X [14]
NoV P Particle University of Cincinnati X [15]
NoV-EV71/VLP combination Institut Pasteur of Shanghai; X [17]
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LP = virus like particle; POC = proof-of-concept; NoV = norovirus; Refs = references.
linical endpoints for rotavirus infection (e.g., the Vesikari scale)
ave been deﬁned and accepted for developing-country popula-
ions, these types of clinical endpoints may  not adequately address
utcomes for mild-to-moderate disease, which is more common
ith NoV compared to rotavirus. However, the incidence of NoV
isease (particularly of mild-to-moderate severity) is high enough
o support such a trial with reasonable numbers—assuming there
s broad enough coverage against circulating and emerging strains.
Another important consideration for a NoV vaccine is that, in
rder to achieve acceptability in developing countries, the vac-
ine formulation should ideally be non-cold-chain-dependent and
ow cost. In addition, the Expanded Programme on Immunization
EPI) vaccine schedule is already quite crowded, and appropri-
te integration of another vaccine into the schedule would need
o be navigated with EPI decision-makers. A combination vaccine
ith parenteral rotavirus vaccine is conceivable, given the simi-
arities in disease indication and early age at which introduction
s needed, and could be a more acceptable solution for low- and
iddle-income countries.
. Status of vaccine R&D activities
Table 1 outlines the NoV vaccine candidates currently under
evelopment. The most advanced candidate is a recombinant VLP
apsid protein vaccine, which has been formulated with Aluminum
ydroxide and Monophosphoryl lipid Adjuvants. It is given in
 two-dose series separated 28 days apart [13]. The candidate
as completed proof-of-concept in two human challenge stud-
es, where protection against disease—particularly, against severe
isease—was achieved [9]. Takeda Vaccines is sponsoring the devel-
pment of this vaccine with signiﬁcant academic collaboration and
nvolvement with the US Department of Defense. The vaccine is
odeled in part on the success of the currently licensed human
apillomavirus (HPV) VLP vaccines. An alternative VLP candidate is
eing developed at Arizona State University using the same con-
truct as the Takeda VLP, but their candidate is produced in a
lant-based vector and has not yet entered clinical development.
A NoV VLP-rotavirus protein combination vaccine candidate is
lso currently in preclinical development, and clinical trials may
egin in the near term [14]. The vaccine is being codeveloped by
he University of Tampere (Finland) and UMN  Pharma (Japan). The
rivalent combination consists of NoV capsid (VP1)-derived VLPs of
I-3 and GII-4 and rotavirus recombinant VP6 (rVP6), a conserved
nd abundant rotavirus protein. Components are expressed indi-
idually in the baculovirus expression system and then combined.
reclinical studies in mice demonstrated strong and high-avidity
oV and rotavirus type-speciﬁc serum IgG responses, and cross-
eactivity with heterologous NoV VLPs and rotaviruses was elicited.
locking antibodies were also described against homologous and
eterologous norovirus VLPs, suggesting broad NoV-neutralizing
ctivity of the sera. Mucosal antibodies of mice immunized with the
rivalent combination vaccine inhibited rotavirus infection in vitro.
ost recently, the developers have described an adjuvant effect of
he rotavirus capsid V6 protein has on the norovirus VLP responsewhich would be advantageous if this obviates the need for addition
of an exogenous adjuvant in the target population [15].
The University of Cincinnati has conducted preclinical immuno-
logical studies on a NoV P particle construct vaccine candidate [16].
This candidate is derived from the protruding (P) domain of the
NoV VP1 capsid protein. P particles can be easily produced in E. coli
expression systems at high yield and thus could represent a man-
ufacturing advantage through relatively low cost of goods. Recent
preclinical research using a gnotobiotic pig model supports het-
erologous cross-reaction of the intranasal P particle vaccine as well
as intestinal and systemic T cell responses. The heterologous pro-
tective efﬁcacy of the P particle vaccine was  comparable to that of
the VLP vaccine in pigs (60%) and the homologous protective efﬁ-
cacy in humans (47%). Clinical development plans for this vaccine
are unknown.
Finally, a novel construct which experimentally combined VLPs
of norovirus GII.4 and enterovirus 71 (EV71, cause of hand, foot
and mouth disease) was recently reported by developers from the
Institut of Pasteur of Shanghai and the Chinese Academy of Sciences
[17]. In a mouse study they were able to demonstrate functional
antibodies to both viruses without evidence of interferences. Such
a novel combination vaccine may  offer additional value to areas of
the world where both these diseases are prevalent, however further
work is needed to understand valency requirements to adequately
cover the six EV71 genogroups that are evolving and geographically
unique around the world [18].
5. Likelihood for ﬁnancing
Currently, Takeda Vaccines is predominantly funding develop-
ment of its VLP-based candidate, though the US Department of
Defense has also provided some support to Ligocyte, which Takeda
bought in 2012. While industry funding would likely be able to
take a vaccine to the developed-country market, further develop-
ment in low- and middle-income country markets would require
funding from a range of sources, including vaccine-manufacturing
partners in potential target markets, state governments, and global
health nonproﬁt organizations. Furthermore, one should not dis-
count the considerable value opportunity that public and private
markets in the emerging economy markets bring to development
and introduction of new vaccines [19]. Similar to rotavirus vac-
cine introduction which has been observed in many emerging
economies, a norovirus vaccine may  make economic and public
health sense to many countries which can afford to introduce such
a vaccine.
Gavi, the Vaccine Alliance has indicated an interest in enteric
vaccines, including one for NoV, though their strongest preference
would be for a combined vaccine, such as the NoV VLP-rotavirus
fusion candidate. Alternatively, combination with or expressionNoV vaccine. Because a NoV vaccine is expected to have a dual
market—both developed and developing countries—there would
likely be scale-up advantages for commercial development and
global distribution.
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